Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TARA with free AI briefings, catalyst countdowns, and dilution alerts.

TARA · Protara Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$143.1M Cash on Hand
25.4mo Cash Runway
Follow TARA by email Get an email when TARA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TARA, unsubscribe in one click. Privacy

📣 What TARA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Choline Chloride Choline Deficiency Phase 2/3 · NCT06910943 Recruiting
Investigator's Choice of Intravesical… Bladder (Urothelial, Transitional Cell) Cancer Phase 3 · NCT07480356 Recruiting
Lyophilized Inactivated Group A Streptococcus… Bladder (Urothelial, Transitional Cell) Cancer Phase 3 · NCT07480356 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TARA holds $143.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.9M/quarter from operations, an estimated runway of 25.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TARA files for a raise →

👥 Who Owns TARA

Insiders 2.3% Other 5%+ holders 5.2% Institutions (151 holders) 76.5% Public and other holders 16%
HolderTypeShares% of sharesAs of
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 4,696,709 7.63% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 3,387,459 5.50% 2026-03-31
Millennium Management LLC 5%+ holder (13G) 3,201,936 5.20% 2026-07-01
Jesse Shefferman
CEO and President, Director · +665,313 options
Insider 991,832 1.61% 2026-06-29
Jacqueline Zummo
Chief R&D Officer · +180,000 options
Insider 94,827 0.15% 2026-04-08
Leonardo Viana Nicacio
Chief Medical Officer · +158,000 options
Insider 78,181 0.13% 2026-01-16
William Conkling
Chief Commercial Officer · +358,000 options
Insider 69,992 0.11% 2026-06-02
Patrick Fabbio
Chief Financial Officer · +175,000 options
Insider 64,115 0.10% 2026-01-26
Richard S Levy
Director · +55,000 options
Insider 51,000 0.08% 2025-05-14
Hannah Fry
VP, Controller · +55,000 options
Insider 42,723 0.07% 2026-01-26

Share count 61,570,351 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TARA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TARA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.